Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9267842 | 0.98 | TAAR1 (0.53) | TAAR1PTGS2MAOBALDH1A1CYP2C9 | |
| SCHEMBL12419500 | 0.89 | ALDH1A1 (0.48) | PTGS2ALDH1A1CYP2C9CYP2C19PPARD | |
| SCHEMBL5491120 | 0.86 | PTGS2 (0.54) | PTGS2MAOBALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL10805292 | 0.85 | PPARD (0.58) | PTGS2ALDH1A1CYP2C9CYP2C19PPARD | |
| SCHEMBL4262134 | 0.85 | ADRB2 (0.58) | PTGS2ALDH1A1CYP2C9CYP2C19PPARD | |
| SCHEMBL8481490 | 0.85 | PTGS2 (0.53) | PTGS2ALDH1A1CYP2C9CYP2C19PPARD | |
| SCHEMBL7328232 | 0.85 | CYP4F2 (0.64) | PTGS2ALDH1A1CYP2C9CYP2C19PPARD | |
| Hydrochloric Acid SCHEMBL6774140 | 0.85 | MAOB (0.53) | PTGS2MAOBALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL7275746 | 0.84 | MAPT (0.44) | TAAR1PTGS2ALDH1A1PPARDMAPT | |
| SCHEMBL8554090 | 0.84 | GAA (0.59) | TAAR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216875-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-26 | — | — | US | disclosed |
| US-20030232788-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| US-5604225-A | DIETETICS; OBESITY | DR. KARL THOMAE GMBH (DE) | 1997-02-18 | — | — | US | disclosed |
| US-5457205-A | Substituted thiazoles useful for treatment of diabetes | DR. KARL THOMAE GMBH (DE) | 1995-10-10 | — | — | US | disclosed |
| US-5399585-A | Anitcoagulants, antiinflammatory, antitumor | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| US-5256812-A | Antitumor agents, cardiovascular disorders; having amidino or guandino groups | HOFFMANN-LA ROCHE INC. (US) | 1993-10-26 | — | — | US | disclosed |
| US-5219852-A | Hypoglycemic agents, treatment of diabetes and obesity | DR. KARL THOMAE GMBH (DE) | 1993-06-15 | — | — | US | disclosed |
| US-5084466-A | Anticoagulants, antiinflammatory agents, atheriosclerosis and antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1992-01-28 | — | — | US | disclosed |
| EP-0239815-B1 | SUBSTITUTED THIAZOLES AND OXAZOLES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1991-07-24 | — | — | EP | disclosed |
| US-4886814-A | LOWER BLOOD SUGAR | DR. KARL THOMAS GMBH (DE) | 1989-12-12 | — | — | US | disclosed |
| EP-0239815-A1 | Substituted thiazoles and oxazoles, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232788-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | DPP3, IAPP, CASP3 | TAAR1 4851/4885PTGS2 2494/4885MAOB 3584/4885 |
| US-20100216875-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | CTSB, BACE2, BACE1 | TAAR1 3151/4885PTGS2 1046/4885MAOB 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.